2026-04-13T22:09:43Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/61462024-06-06T08:41:56Zcom_2072_378070com_2072_378040col_2072_378092

Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design Tabernero Caturla, Josep Prager, Gerald W Leger, Catherine Fakih, Marwan Taieb, Julien Ciardiello, Fortunato Institut Català de la Salut [Tabernero J] Vall d'Hebron Hospital Universitari, Barcelona, Spain. Institute of Oncology (VHIO), Barcelona, Spain. [Taieb J] Service d'hépatogastroentérologie et d'oncologie digestive, Université de Paris, Paris Descartes University, Georges Pompidou European Hospital, 20 rue Leblanc, Paris, France. [Prager GW] Department of Medicine I, Comprehensive Cancer Centre Vienna, Medical University Vienna, Josefstaedter Str. 23/15, Vienna, Austria. [Ciardiello F] Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Via S. Pansini, Naples, Italy. [Fakih M] Briskin Center for Clinical Research, Section Head and GI Medical Oncology, City of Hope Comprehensive Cancer Center, 1500 E Duarte St, Duarte, CA, USA. [Leger C] Institut de Recherches Internationales Servier, 50 rue Carnot, Suresnes Cedex, France Vall d'Hebron Barcelona Hospital Campus Medicaments antineoplàstics - Ús terapèutic Recte - Càncer Còlon - Càncer DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols Other subheadings::Other subheadings::/therapeutic use ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::protocolos clínicos::protocolos antineoplásicos::protocolos de quimioterapia antineoplásica combinada Otros calificadores::Otros calificadores::/uso terapéutico Bevacizumab; Càncer colorectal metastàtic; Trifluridine/tipiracil Bevacizumab; Cáncer colorrectal metastásico; Trifluridine/tipiracil Bevacizumab; Metastatic colorectal cancer; Trifluridine/tipiracil Trifluridine/tipiracil (FTD/TPI) is an orally active formulation of trifluridine, a thymidine-based nucleoside analog, and tipiracil hydrochloride, a thymidine phosphorylase inhibitor that increases the bioavailability of trifluridine. Preliminary studies of FTD/TPI plus bevacizumab have produced encouraging results in the treatment of refractory metastatic colorectal cancer. Here, we describe the design of the multinational Phase III SUNLIGHT, an open-label study of FTD/TPI plus bevacizumab as third-line treatment for patients with unresectable metastatic colorectal cancer. A total of 490 patients will be randomized 1:1 to receive either FTD/TPI plus bevacizumab, or FTD/TPI monotherapy. The primary objective is to significantly improve overall survival with FTD/TPI plus bevacizumab compared with FTD/TPI monotherapy. The first patient was enrolled in November 2020. 2021-07-09T12:37:00Z 2021-07-09T12:37:00Z 2021-06 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Tabernero J, Taieb J, Prager GW, Ciardiello F, Fakih M, Leger C, et al. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. Futur Oncol. 2021 Jun;17(16):1977–1985. 1744-8301 https://hdl.handle.net/11351/6146 10.2217/fon-2020-1238 33569986 000616966800001 eng Future Oncology;17(16) https://www.futuremedicine.com/doi/10.2217/fon-2020-1238 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf Future Medicine Scientia